Arvinas Inc (ARVN)

$12.18 -0.30 (-2.40%)
Market Cap 779.05M
Revenue (ttm) 262.60M
Net Income (ttm) -80.80M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -30.77%
Debt to Equity Ratio 0.00
Volume 689,300
Avg Vol 797,504
Day's Range N/A - N/A
Shares Out 63.96M
Stochastic %K 10%
Beta 1.87
Analysts Sell
Price Target $14.56

Company Profile

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein fo...

Industry: Biotechnology
Sector: Healthcare
Phone: 203 535 1456
Address:
5 Science Park, 395 Winchester Avenue, New Haven, United States
NewGuyHere94
NewGuyHere94 Mar. 12 at 8:30 PM
$ARVN insider buys, never a bad thing
0 · Reply
HedgeFollow
HedgeFollow Mar. 10 at 5:25 PM
🔍 New Buys 🔎 4th consecutive Insider Buy on $ABTC reported within 1 week. Good signal. And first on $ARVN Arvinas in a very long time. Usually they are only selling.
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Mar. 10 at 2:11 PM
$ARVN
1 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Mar. 9 at 2:29 PM
$ARVN slowly but surely
1 · Reply
erevnon
erevnon Mar. 5 at 7:18 PM
Citigroup maintains Arvinas $ARVN at Buy and raises the price target from $15 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Mar. 4 at 7:14 PM
$ARVN
1 · Reply
SuperGreenToday
SuperGreenToday Mar. 4 at 2:28 PM
$ARVN Share Price: $13.36 Contract Selected: Oct 16, 2026 $15 Calls Buy Zone: $1.42 – $1.75 Target Zone: $2.54 – $3.10 Potential Upside: 69% ROI Time to Expiration: 225 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Mar. 3 at 8:36 PM
$ARVN
0 · Reply
BioTechHealthX
BioTechHealthX Mar. 1 at 3:19 PM
$ARVN Arvinas stock is hovering near $12 after a volatile earnings reaction, but with multiple 2026 clinical data catalysts and a cash runway into 2028, ARVN could be one of the most intriguing small-cap biotech stocks to watch. Is targeted protein degradation about to unlock major upside? https://biotechhealthx.com/biotech-news/is-arvinas-inc-arvn-a-smart-long-term-investment/
0 · Reply
BioTechHealthX
BioTechHealthX Mar. 1 at 3:15 PM
$ADAP $ARVN $CING $CRVS $ETON A single FDA approval can double a small-cap biotech stock overnight. Discover 10 high-risk, high-reward FDA catalyst stocks with confirmed PDUFA dates this quarter that traders are watching for breakout moves, volatility spikes, and potential buyout speculation. https://biotechhealthx.com/biotech-news/top-10-small-cap-fda-catalyst-biotech-stocks/
1 · Reply
Latest News on ARVN
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Mar 11, 2026, 7:00 AM EDT - 4 days ago

Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Arvinas, Inc. (ARVN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Mar 10, 2026, 5:30 PM EDT - 5 days ago

Arvinas, Inc. (ARVN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Arvinas, Inc. (ARVN) Q4 2025 Earnings Call Transcript

Feb 24, 2026, 5:37 PM EST - 19 days ago

Arvinas, Inc. (ARVN) Q4 2025 Earnings Call Transcript

Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Feb 24, 2026, 7:00 AM EST - 19 days ago

Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Arvinas to Participate in Upcoming Investor Conferences

Feb 23, 2026, 7:00 AM EST - 20 days ago

Arvinas to Participate in Upcoming Investor Conferences

Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Feb 17, 2026, 7:00 AM EST - 26 days ago

Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director

Feb 12, 2026, 7:00 AM EST - 4 weeks ago

Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director

Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition

Dec 6, 2025, 8:05 AM EST - 3 months ago

Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition

Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference

Nov 26, 2025, 7:00 AM EST - 3 months ago

Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference

Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)

Nov 24, 2025, 7:00 AM EST - 3 months ago

Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)

Arvinas, Inc. (ARVN) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 3:01 PM EST - 4 months ago

Arvinas, Inc. (ARVN) Q3 2025 Earnings Call Transcript

Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 5, 2025, 7:00 AM EST - 4 months ago

Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting

Nov 3, 2025, 4:00 PM EST - 4 months ago

Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting

Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025

Oct 29, 2025, 7:00 AM EDT - 4 months ago

Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025

Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 24, 2025, 4:00 PM EDT - 5 months ago

Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 22, 2025, 4:00 PM EDT - 5 months ago

Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy

Oct 20, 2025, 4:15 AM EDT - 5 months ago

Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy

PFE

Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress

Oct 13, 2025, 7:00 AM EDT - 5 months ago

Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress

Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders®

Oct 5, 2025, 2:00 PM EDT - 5 months ago

Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders®

Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders®

Oct 1, 2025, 7:00 AM EDT - 5 months ago

Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders®

Arvinas, Pfizer to grant commercial rights of experimental breast cancer drug to third party

Sep 17, 2025, 5:50 PM EDT - 6 months ago

Arvinas, Pfizer to grant commercial rights of experimental breast cancer drug to third party

PFE

Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation

Sep 17, 2025, 4:30 PM EDT - 6 months ago

Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation

Arvinas, Inc. (ARVN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 9, 2025, 10:12 AM EDT - 6 months ago

Arvinas, Inc. (ARVN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

Aug 8, 2025, 4:05 PM EDT - 7 months ago

Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

Arvinas, Inc. (ARVN) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 1:24 PM EDT - 7 months ago

Arvinas, Inc. (ARVN) Q2 2025 Earnings Call Transcript

Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 6, 2025, 7:00 AM EDT - 7 months ago

Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 30, 2025, 4:05 PM EDT - 8 months ago

Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025

Arvinas Announces Retirement of Chief Executive Officer and Succession Plan

Jul 9, 2025, 7:00 AM EDT - 8 months ago

Arvinas Announces Retirement of Chief Executive Officer and Succession Plan

Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress

Jun 13, 2025, 7:00 AM EDT - 9 months ago

Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress

Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

Jun 6, 2025, 7:00 AM EDT - 10 months ago

Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting

Jun 5, 2025, 8:28 AM EDT - 10 months ago

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting

Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression

May 31, 2025, 8:06 AM EDT - 10 months ago

Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression

PFE

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

May 31, 2025, 8:00 AM EDT - 10 months ago

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

Arvinas to Present at Jefferies Global Healthcare Conference

May 30, 2025, 7:00 AM EDT - 10 months ago

Arvinas to Present at Jefferies Global Healthcare Conference

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Shareholders to Inquire about Securities Investigation

May 16, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Shareholders to Connect

May 15, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Shareholders to Reach Out

May 14, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Shareholders to Learn More About the Investigation

May 13, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Shareholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Investors to Learn More About the Investigation

May 12, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Investors to Learn More About the Investigation

Arvinas, Inc. (ARVN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 11, 2025, 10:00 AM EDT - 11 months ago

Arvinas, Inc. (ARVN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

NewGuyHere94
NewGuyHere94 Mar. 12 at 8:30 PM
$ARVN insider buys, never a bad thing
0 · Reply
HedgeFollow
HedgeFollow Mar. 10 at 5:25 PM
🔍 New Buys 🔎 4th consecutive Insider Buy on $ABTC reported within 1 week. Good signal. And first on $ARVN Arvinas in a very long time. Usually they are only selling.
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Mar. 10 at 2:11 PM
$ARVN
1 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Mar. 9 at 2:29 PM
$ARVN slowly but surely
1 · Reply
erevnon
erevnon Mar. 5 at 7:18 PM
Citigroup maintains Arvinas $ARVN at Buy and raises the price target from $15 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Mar. 4 at 7:14 PM
$ARVN
1 · Reply
SuperGreenToday
SuperGreenToday Mar. 4 at 2:28 PM
$ARVN Share Price: $13.36 Contract Selected: Oct 16, 2026 $15 Calls Buy Zone: $1.42 – $1.75 Target Zone: $2.54 – $3.10 Potential Upside: 69% ROI Time to Expiration: 225 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Mar. 3 at 8:36 PM
$ARVN
0 · Reply
BioTechHealthX
BioTechHealthX Mar. 1 at 3:19 PM
$ARVN Arvinas stock is hovering near $12 after a volatile earnings reaction, but with multiple 2026 clinical data catalysts and a cash runway into 2028, ARVN could be one of the most intriguing small-cap biotech stocks to watch. Is targeted protein degradation about to unlock major upside? https://biotechhealthx.com/biotech-news/is-arvinas-inc-arvn-a-smart-long-term-investment/
0 · Reply
BioTechHealthX
BioTechHealthX Mar. 1 at 3:15 PM
$ADAP $ARVN $CING $CRVS $ETON A single FDA approval can double a small-cap biotech stock overnight. Discover 10 high-risk, high-reward FDA catalyst stocks with confirmed PDUFA dates this quarter that traders are watching for breakout moves, volatility spikes, and potential buyout speculation. https://biotechhealthx.com/biotech-news/top-10-small-cap-fda-catalyst-biotech-stocks/
1 · Reply
buyandsold
buyandsold Feb. 26 at 6:01 AM
$ARVN Arvinas and Pfizer plan to jointly select third party for the out-licensing and commercialization of vepdegestrant Who shall be selected for the Scarlet Letter! My guess is a newly formed entity with no commercialization track record that promises big royalties so that Noah can continue calling Vepdeg a financial asset.
0 · Reply
buyandsold
buyandsold Feb. 26 at 3:50 AM
$ARVN no dilution risk, also no risk to make any money. Warm to the fireside of money burning for 2.5 more years. The only way to win here is join the company and draw a salary. They even pay you after you retire.
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Feb. 25 at 4:56 PM
$ARVN from $10 to $13.50 is nice. We are curing breast cancer here. Let’s ride
0 · Reply
erevnon
erevnon Feb. 25 at 2:46 PM
Evercore ISI Group maintains Arvinas $ARVN at Outperform and raises the price target from $14 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
erevnon
erevnon Feb. 25 at 2:18 PM
Wedbush maintains Arvinas $ARVN at Neutral and raises the price target from $9 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Feb. 24 at 9:53 PM
$ARVN
1 · Reply
biopuzzle
biopuzzle Feb. 24 at 7:23 PM
$ARVN The Journey continues... "No turning back, no turning back"😉🫶
0 · Reply
BioSpecialOne
BioSpecialOne Feb. 24 at 2:14 PM
$ARVN nice recovery! clear path towards PDUFA!
0 · Reply
TheDizPlinTrader
TheDizPlinTrader Feb. 24 at 1:41 PM
$ARVN 🧬 1 Hour Levels Price: $11.20 Support: $10.70 Resistance: $12.00 👉 Tap follow to keep these 1-hour levels on your feed.
0 · Reply
NewGuyHere94
NewGuyHere94 Feb. 24 at 1:17 PM
$ARVN always a scared sell off after an earnings presentation, the pipeline is full of massive opportunities this year, HUGE year for ARVN in 2026.
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Feb. 24 at 1:04 PM
$ARVN @GreggTwits this one is breast cancer June pdufa Jumping in now to take advantage of the earnings dip
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Feb. 24 at 1:03 PM
$ARVN okay I’m in
1 · Reply